Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years

TY - JOUR

T1 - Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years

AU - Passweg, Jakob R

AU - Baldomero, Helen

AU - Chabannon, Christian

AU - Basak, Grzegorz W

AU - de la Cámara, Rafael

AU - Corbacioglu, Selim

AU - Dolstra, Harry

AU - Duarte, Rafael

AU - Glass, Bertram

AU - Greco, Raffaella

AU - Lankester, Arjan C

AU - Mohty, Mohamad

AU - Peffault de Latour, Régis

AU - Snowden, John A

AU - Yakoub-Agha, Ibrahim

AU - Kröger, Nicolaus

AU - European Society for Blood and Marrow Transplantation (EBMT)

PY - 2021/7

Y1 - 2021/7

N2 - Numbers of Hematopoietic cell transplantation (HCT) in Europe and collaborating countries continues to rise with 48,512 HCT in 43,581 patients, comprising of 19,798 (41%) allogeneic and 28,714 (59%) autologous, reported by 700 centers in 51 countries during 2019. Main indications were myeloid malignancies 10,764 (25%), lymphoid malignancies 27,895 (64%), and nonmalignant disorders 3173 (7%). A marked growth in CAR-T cellular therapies from 151 in 2017 to 1134 patients in 2019 is observed. This year's analyses focus on changes over 30 years. Since the first survey in 1990 where 143 centers reported 4234 HCT, the number has increased to 700 centers and 48,512 HCT. Transplants were reported in 20 countries in 1990, and 51, 30 years later. More than 800,000 HCT in 715,000 patients were reported overall. Next to the massive expansion of HCT technology, most notable developments include the success of unrelated donor and haploidentical HCT, an increase followed by decrease in the number of cord blood transplants, use of reduced intensity HCT in older patients, and the phenomenal rise in cellular therapy. This annual report of the European Society for Blood and Marrow Transplantation (EBMT) reflects current activity and highlights important trends vital for health care planning.

AB - Numbers of Hematopoietic cell transplantation (HCT) in Europe and collaborating countries continues to rise with 48,512 HCT in 43,581 patients, comprising of 19,798 (41%) allogeneic and 28,714 (59%) autologous, reported by 700 centers in 51 countries during 2019. Main indications were myeloid malignancies 10,764 (25%), lymphoid malignancies 27,895 (64%), and nonmalignant disorders 3173 (7%). A marked growth in CAR-T cellular therapies from 151 in 2017 to 1134 patients in 2019 is observed. This year's analyses focus on changes over 30 years. Since the first survey in 1990 where 143 centers reported 4234 HCT, the number has increased to 700 centers and 48,512 HCT. Transplants were reported in 20 countries in 1990, and 51, 30 years later. More than 800,000 HCT in 715,000 patients were reported overall. Next to the massive expansion of HCT technology, most notable developments include the success of unrelated donor and haploidentical HCT, an increase followed by decrease in the number of cord blood transplants, use of reduced intensity HCT in older patients, and the phenomenal rise in cellular therapy. This annual report of the European Society for Blood and Marrow Transplantation (EBMT) reflects current activity and highlights important trends vital for health care planning.

KW - Aged

KW - Europe

KW - Hematopoietic Stem Cell Transplantation

KW - Humans

KW - Surveys and Questionnaires

KW - Transplantation, Homologous

KW - Unrelated Donors

U2 - 10.1038/s41409-021-01227-8

DO - 10.1038/s41409-021-01227-8

M3 - SCORING: Journal article

C2 - 33623153

VL - 56

SP - 1651

EP - 1664

JO - BONE MARROW TRANSPL

JF - BONE MARROW TRANSPL

SN - 0268-3369

IS - 7

ER -